Canaccord raised the firm’s price target on Exagen (XGN) to $15 from $11 and keeps a Buy rating on the shares. The firm updated its model ahead of Q3 results noting that the life science tools secot remains challenged amid multiple headwinds including tariffs, funding uncertainty, and China issues.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XGN: